Im

NOV 3 0 2005 W

PATENT ATTORNEY DOCKET NO.: 056291-5103-01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:	) Confirmation	on No. 3791
ALCARAZ et al.	) )	
Appln. No.: 10/813,426	) Group Art U	Jnit: 1626
Filed: March 31, 2004	) Examiner:	Nolan, Jason M.
FOR: ADMANTANE DERIVATIVES	)	
Commissioner for Patents U.S. Patent and Trademark Office Randolph Building – Customer Service Window 401 Dulany Street Alexandria, Virginia 22304 – MAIL STOP	Date:	November 30, 2005
Sir:		

## RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

This is in response to the One-Month Action dated October 31, 2005. In response to the restriction requirement set forth therein, Applicants elect the invention of Group I, claims 1-4, 6, 10 and 12 drawn to compounds and compositions of the formula I, and reserve the right, upon allowance of compound/composition claims, to rejoin the method of using claims of Group II and the process for making claims of Group III of commensurate compound scope. Pursuant to the request for election of species, Applicants elect the compound of specification Example 52, being:

2-Chloro-5-[3-(cyclohexylamino)propyl]-N-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl)-benzamide. Applicants reserve the right to traverse and/or to request modification of the scope of the "inventive concept" when defined by the Examiner.

Please amend the above-identified application as follows: